Publications

View and download slide summaries of the latest original articles focusing on therapies in immune-mediated inflammatory diseases including rheumatology, dermatology, and gastroenterology. All materials produced by the team are subsequently reviewed and approved by individual Steering Committee members.

April 2026

Incidence of major adverse cardiovascular events in patients with rheumatoid arthritis treated with Janus kinase inhibitors compared to biologic disease-modifying antirheumatic drugs: data from an international collaboration of registries (the "JAK-pot" study)

Arthritis Rheumatol. 2025 doi: 10.1002/art.43188 Epub ahead of print

Aymon R,

Salis Z,

Leeb BF,

Rotar Z,

Nina T,

Data from an international collaboration of registries show no evidence of an increase in CV events during the first 2 years of use with JAKi, compared to TNFi, in the general RA population.

Keywords:

November 2025

Long‑term comparative analysis of secukinumab versus TNFα inhibitors in patients with spondyloarthritis: Treatment persistence is differentially affected by disease phenotype, obesity and sex

Arthritis Research & Therapy 2025;27:202 Doi: 10.1186/s13075-025-03664-y

Repa A,

Kalligianni-Sofikiti K,

Data by Flouri et al. support greater drug persistence with secukinumab than with TNF inhibitors in patients with axSpA and peripheral spondyloarthritis, both with respect to efficacy- and safety-related discontinuations, while the achievement of 6-month treatment targets was comparable. Flouri et al. compared long term treatment persistence, efficacy and safety between secukinumab and TNF inhibitors in a cohort of patients with SpA treated in real life.